Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Oxford University spinout will use the investment to further develop its exosome technology, capable of delivering drugs to previously inaccessible parts of the body.

Evox Therapeutics, an Oxford University spinout which is using exosomes – the body’s natural vesicular delivery system – to deliver drugs to hard to reach parts of the body, has raised £35.5m in its Series B financing round.

Read more (Oxford University Innovation website)